Abstract 548P
Background
The Immunoscore® is a validated prognostic stratification tool for colorectal cancer (CRC), yet its adoption is impeded by complex commercial software and patient reimbursement challenges. Utilizing open-source methods, this study aimed to explore whether immune cell scoring can be facilitated by focusing on single T-cell markers, to provide a simplified yet prognostic model in non-metastatic CRC.
Methods
We conducted a multicentric prospective cohort study in non-metastatic CRC patients who underwent curative surgical resection. CD3+ and CD8+ tumor infiltrating lymphocytes [TILs] were quantified in both invasive margin [IM] and tumor core [TC] using QuPath. A composite score, termed immune score (IS), mirroring the methods employed for the Immunoscore®, was calculated based on the TIL densities [CD3IM, CD8IM, CD3TC, CD8TC]. We used a split-sample approach to estimate adjusted hazard ratios of cancer-specific survival [CSS] in a training and a validation set. Classification and regression tree analysis [CART] was performed to select the most prognostic TIL. The model incorporating the CART-selected TIL was compared to a two-tiered IS model for overall performance [Brier score] and discrimination [concordance probability estimate, CPE].
Results
During a median follow-up time of 9.0 years, out of 1260 patients, there were 203 CRC-specific deaths. CART-selected CD8IM was the most prognostic TIL at a cut-off of 231 cells/mm2. Patients with CD8IMHi had better CSS than CD8IMLow in both training [HR 0.58, 95% CI 0.40-0.84] and validation sets [HR 0.35, 95% CI 0.21-0.60]. Brier scores of CD8IM and IS survival models were comparable in both training and validation cohort whereas the survival discrimination of CD8IM slightly outperformed the IS in the validation set [CPE: CD8IM 0.748, IS 0.730].
Conclusions
This study found that CD8IM TILs might be a marker as good as the more complex IS for predicting CRC prognosis in non-metastatic CRC patients CD8IM should be further explored as a simple predictive biomarker of adjuvant therapy benefits to advance personalized medicine in early-stage CRC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
German Research Council (HO 5117/2-2).
Disclosure
M. Hoffmeister: Financial Interests, Institutional, Funding, Grant number: HO 5117/2-2: German Research Council. All other authors have declared no conflicts of interest.
Resources from the same session
557P - Three-year update of real-world evaluation of ColonAiQ for colorectal cancer screening in asymptomatic individuals
Presenter: Baohua Wang
Session: Poster session 16
558P - Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: Subgroup analysis from CIRCULATE-Japan GALAXY
Presenter: Kozo Kataoka
Session: Poster session 16
561P - Liquid biopsy tracking of immunotherapy-induced T cell dynamics in MSS colorectal and endometrial tumors
Presenter: Holger Heyn
Session: Poster session 16
562P - Acquired genomic alterations on first-line chemotherapy (CT) + cetuximab in advanced colorectal cancer (mCRC): Circulating tumor (ct)DNA analysis of the randomized phase II trial TIME-PRODIGE-28
Presenter: Valerie Boige
Session: Poster session 16
564P - Short-course radiotherapy combined with chemotherapy and PD-1 inhibitor in proficient mismatch repair or microsatellite stable (pMMR/MSS) low-lying early rectal cancer: Preliminary findings from a prospective, multi-center, phase II trial (TORCH-E)
Presenter: Fan Xia
Session: Poster session 16
565P - Neoadjuvant chemotherapy, excision, and observation for early rectal cancer: The phase II NEO trial (CCTG CO.28) results after minimum 3 years follow up
Presenter: Carl Brown
Session: Poster session 16
566P - Impact of weekly irinotecan’s cycles during preoperative chemoradiotherpy in locally advanced rectal cancer: A post-hoc analysis of the CinClare study
Presenter: Ji Zhu
Session: Poster session 16